Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | VP, Chief Accounting Officer | April 27, 2026 | April 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
WEST PHARMACEUTICAL SERVICES INC
Report date April 27, 2026 · Filed April 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,522.81 |
Ending reported balance
After 2026-04-27 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-27 · Exercise / conversion · Acquired 896 · Balance 2,418.81 Row 2 · 2026-04-27 · Sale · Disposed 896 · Balance 1,522.81 F1: The price reported in column 4 is a weighted average price. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $173.22 · Expires 2030-02-18 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-27 · Exercise / conversion · Disposed 896 · Balance 0 F2: This award granted on February 18, 2020 vested in four equal annual installments beginning on February 18, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price.
F2: This award granted on February 18, 2020 vested in four equal annual installments beginning on February 18, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 27, 2026 Filed Apr 29, 2026 16:19 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 896 | $0.00 Strike: $173.22 | $0.00 |
DisclosureSEC source: 0000105770-26-000053 · form4.xml · derivative · entry 3 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 896 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This award granted on February 18, 2020 vested in four equal annual installments beginning on February 18, 2021. Read SEC document |
| April 27, 2026 Filed Apr 29, 2026 16:19 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 896 | $300.67 | $269,399.24 |
DisclosureSEC source: 0000105770-26-000053 · form4.xml · nonDerivative · entry 2 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,522.81 F1 · price: The price reported in column 4 is a weighted average price. Read SEC document |
| April 27, 2026 Filed Apr 29, 2026 16:19 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 896 | $173.22 | $155,205.12 |
DisclosureSEC source: 0000105770-26-000053 · form4.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,418.81 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 16:22 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Option (Right to Buy) · Derivative | 808 | $0.00 Strike: $254.34 | $0.00 |
DisclosureSEC source: 0000105770-26-000033 · form4.xml · derivative · entry 2 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 808 Underlying: Common Stock · 808 shares Expires 2036-03-01 F3 · derivative.exercise_date: The stock option vests in four equal annual installments beginning on March 1, 2027. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 16:22 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantRst. Stock Unit · Derivative | 340 | $0.00 | $0.00 |
DisclosureSEC source: 0000105770-26-000033 · form4.xml · derivative · entry 1 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340 Underlying: Common Stock · 340 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2027. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2027. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:40 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionRst. Stock Unit · Derivative | 89.328 | $0.00 | $0.00 |
DisclosureSEC source: 0000105770-26-000023 · form4.xml · derivative · entry 3 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267.972 Underlying: Common Stock · 89.328 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On February 18, 2025, the reporting person was granted 356 restricted stock units, vesting in four equal annual installments (plus dividend equivalents) on February 20th each year. F2 · derivative.expiration_date: On February 18, 2025, the reporting person was granted 356 restricted stock units, vesting in four equal annual installments (plus dividend equivalents) on February 20th each year. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:40 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 30.184 | $241.12 | $7,277.97 |
DisclosureSEC source: 0000105770-26-000023 · form4.xml · nonDerivative · entry 2 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,522.81 Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:40 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 89.328 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000105770-26-000023 · form4.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,552.994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 00:02 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 50.579 | $243.19 | $12,300.31 |
DisclosureSEC source: 0000105770-26-000018 · form4.xml · nonDerivative · entry 2 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,462.103 Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 00:02 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 149.684 | $0.00 | $0.00 |
DisclosureSEC source: 0000105770-26-000018 · form4.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,512.682 F1 · shares: These shares result from performance stock units (PSUs) which vested at the end of the respective 2023-2025 PSU performance period and were payable on the transaction date shown. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:09 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantRst. Stock Unit · Derivative | 356 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006118 · form4.xml · derivative · entry 4 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356 Underlying: Common Stock · 356 shares Expires not disclosed F1 · derivative.exercise_date: This award vests in four equal installments beginning on February 18, 2026. F1 · derivative.expiration_date: This award vests in four equal installments beginning on February 18, 2026. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:09 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Option (Right to Buy) · Derivative | 822 | $0.00 Strike: $211.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006118 · form4.xml · derivative · entry 3 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 822 Underlying: Common Stock · 822 shares Expires 2035-02-18 F1 · derivative.exercise_date: This award vests in four equal installments beginning on February 18, 2026. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:09 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 27.727 | $211.00 | $5,850.40 |
DisclosureSEC source: 0001127602-25-006118 · form4.xml · nonDerivative · entry 2 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,363.025 Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:09 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 82.054 | $211.00 | $17,313.39 |
DisclosureSEC source: 0001127602-25-006118 · form4.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,390.752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 15:46 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 675 | $0.00 Strike: $173.22 | $0.00 |
DisclosureSEC source: 0001127602-24-009590 · form4.xml · derivative · entry 3 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 896 Underlying: Stock Options (Right to Buy) · 675 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 15:46 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 815 | $358.82 | $292,435.86 |
DisclosureSEC source: 0001127602-24-009590 · form4.xml · nonDerivative · entry 2 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,308.698 F1 · security: 2021 PSUs (PP20) award vesting net of taxes withheld. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 15:46 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 675 | $173.22 | $116,923.50 |
DisclosureSEC source: 0001127602-24-009590 · form4.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,123.698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: 2021 PSUs (PP20) award vesting net of taxes withheld. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 23:47 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to Buy) · Derivative | 1,020 | $0.00 Strike: $350.18 | $0.00 |
DisclosureSEC source: 0001127602-24-006414 · form4.xml · derivative · entry 2 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,020 Underlying: Stock Options (Right to Buy) · 1,020 shares Expires 2034-02-20 F2 · derivative.exercise_date: This grant vests in four equal installments beginning on February 20, 2025. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 23:47 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 179 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006414 · form4.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,448.698 F1 · security: 2021 PSUs (PP20) award vesting net of taxes withheld. Read SEC document |
| December 04, 2023 Filed Dec 21, 2023 17:54 UTC Amendment | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 341 | $0.00 Strike: $173.22 | $0.00 |
DisclosureSEC source: 0001127602-23-030255 · form4a.xml · derivative · entry 5 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,571 Underlying: Stock Options (Right to Buy) · 341 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This is a revision to accurately reflect option exercises and sales that Chad Winters requested on December 1, 2023 that were completed on December 4, 2023 due to a record-keeping system outage. Read SEC document |
| December 04, 2023 Filed Dec 21, 2023 17:54 UTC Amendment | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 456 | $0.00 Strike: $143.43 | $0.00 |
DisclosureSEC source: 0001127602-23-030255 · form4a.xml · derivative · entry 4 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Stock Options (Right to Buy) · 456 shares Expires 2029-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This is a revision to accurately reflect option exercises and sales that Chad Winters requested on December 1, 2023 that were completed on December 4, 2023 due to a record-keeping system outage. Read SEC document |
| December 04, 2023 Filed Dec 21, 2023 17:54 UTC Amendment | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 341 | $173.22 | $59,068.02 |
DisclosureSEC source: 0001127602-23-030255 · form4a.xml · nonDerivative · entry 3 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,282.698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This is a revision to accurately reflect option exercises and sales that Chad Winters requested on December 1, 2023 that were completed on December 4, 2023 due to a record-keeping system outage. Read SEC document |
| December 04, 2023 Filed Dec 21, 2023 17:54 UTC Amendment | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 1,013 | $349.00 | $353,541.25 |
DisclosureSEC source: 0001127602-23-030255 · form4a.xml · nonDerivative · entry 2 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,269.698 F1 · date: This is a revision to accurately reflect option exercises and sales that Chad Winters requested on December 1, 2023 that were completed on December 4, 2023 due to a record-keeping system outage. Read SEC document |
| December 04, 2023 Filed Dec 21, 2023 17:54 UTC Amendment | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 456 | $143.43 | $65,404.08 |
DisclosureSEC source: 0001127602-23-030255 · form4a.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,941.698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This is a revision to accurately reflect option exercises and sales that Chad Winters requested on December 1, 2023 that were completed on December 4, 2023 due to a record-keeping system outage. Read SEC document |
| December 01, 2023 Filed Dec 6, 2023 00:33 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 341 | $0.00 Strike: $173.22 | $0.00 |
DisclosureSEC source: 0001127602-23-028965 · form4.xml · derivative · entry 5 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,571 Underlying: Stock Options (Right to Buy) · 341 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2023 Filed Dec 6, 2023 00:33 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 456 | $0.00 Strike: $143.43 | $0.00 |
DisclosureSEC source: 0001127602-23-028965 · form4.xml · derivative · entry 4 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Stock Options (Right to Buy) · 456 shares Expires 2029-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2023 Filed Dec 6, 2023 00:33 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 341 | $173.22 | $59,068.02 |
DisclosureSEC source: 0001127602-23-028965 · form4.xml · nonDerivative · entry 3 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,282.698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2023 Filed Dec 6, 2023 00:33 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 1,013 | $349.00 | $353,541.25 |
DisclosureSEC source: 0001127602-23-028965 · form4.xml · nonDerivative · entry 2 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,269.698 Read SEC document |
| December 01, 2023 Filed Dec 6, 2023 00:33 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 456 | $143.43 | $65,404.08 |
DisclosureSEC source: 0001127602-23-028965 · form4.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,941.698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2023 Filed May 31, 2023 20:37 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to buy) · Derivative | 872 | $0.00 Strike: $143.43 | $0.00 |
DisclosureSEC source: 0001562180-23-004626 · primarydocument.xml · derivative · entry 3 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 456 Underlying: Common Stock · 872 shares Expires 2029-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2023 Filed May 31, 2023 20:37 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 872 | $339.51 | $296,052.72 |
DisclosureSEC source: 0001562180-23-004626 · primarydocument.xml · nonDerivative · entry 2 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,448.711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2023 Filed May 31, 2023 20:37 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 872 | $143.43 | $125,070.96 |
DisclosureSEC source: 0001562180-23-004626 · primarydocument.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,320.711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2023 Filed May 9, 2023 19:42 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 10 | $368.46 | $3,684.60 |
DisclosureSEC source: 0001562180-23-004003 · primarydocument.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,448.711 F1 · kind: Shares withheld solely for the purpose of satisfying tax liability due upon vesting of restricted stock award. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:29 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 1,012 | $0.00 Strike: $306.68 | $0.00 |
DisclosureSEC source: 0001562180-23-001798 · primarydocument.xml · derivative · entry 2 Winters Chad · CIK 0001811424 · VP, CAO & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012 Underlying: Stock Options (Right to Buy) · 1,012 shares Expires 2033-02-21 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 21, 2024. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:29 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 476 | $306.68 | $145,979.68 |
DisclosureSEC source: 0001562180-23-001798 · primarydocument.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, CAO & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,458.711 F1 · shares: 2020 PSUs (PP19) award vesting net of taxes withheld Read SEC document |
| October 31, 2022 Filed Nov 1, 2022 18:59 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 47 | $225.51 | $10,598.97 |
DisclosureSEC source: 0001562180-22-007398 · primarydocument.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, CAO & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 982.711 F1 · kind: Shares withheld solely for the purpose of satisfying tax liability on dividend accrued on restricted stock award vested on 10/31/2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 15:28 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 10 | $314.76 | $3,147.60 |
DisclosureSEC source: 0001562180-22-003850 · primarydocument.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, CAO & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062.777 F1 · kind: Shares withheld solely for the purpose of satisfying tax liability on dividend accrued on restricted stock award vested on 5/5/2022. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:56 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 1,036 | $0.00 Strike: $369.13 | $0.00 |
DisclosureSEC source: 0001562180-22-001885 · primarydocument.xml · derivative · entry 1 Winters Chad · CIK 0001811424 · VP, CAO & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036 Underlying: Stock Options (Right to Buy) · 1,036 shares Expires 2032-02-22 F1 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 20:28 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 414 | $369.13 | $152,819.82 |
DisclosureSEC source: 0001562180-22-001859 · primarydocument.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, CAO & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,072.777 F1 · shares: 2019 PSUs (PP18) award vesting net of taxes withheld Read SEC document |
| October 29, 2021 Filed Nov 1, 2021 19:05 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 47 | $429.88 | $20,204.36 |
DisclosureSEC source: 0001562180-21-006716 · primarydocument.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, CAO & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658.777 F1 · kind: Shares withheld solely for the purpose of satisfying tax liability on dividend accrued on restricted stock award vested on 10/29/2021 Read SEC document |
| May 05, 2021 Filed May 7, 2021 18:27 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 10 | $328.60 | $3,286.00 |
DisclosureSEC source: 0001562180-21-003318 · primarydocument.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, CAO & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705.777 F1 · kind: Shares withheld solely for the purpose of satisfying tax liability due upon vesting of restricted stock award. Read SEC document |
| March 12, 2021 Filed Mar 19, 2021 10:04 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 170 | $261.62 | $44,475.40 |
DisclosureSEC source: 0001562180-21-002368 · primarydocument.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, CAO & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714.8868 F1 · shares: Portion of bonus paid in stock with a conversion date of March 8, 2021 Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:48 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 1,388 | $0.00 Strike: $274.29 | $0.00 |
DisclosureSEC source: 0001562180-21-001595 · primarydocument.xml · derivative · entry 1 Winters Chad · CIK 0001811424 · VP, CAO & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,388 Underlying: Common Stock · 1,388 shares Expires 2031-02-23 F1 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/23/2022. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 15:34 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 47 | $275.23 | $12,935.81 |
DisclosureSEC source: 0001562180-20-006462 · primarydocument.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, CAO & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544.8868 F1 · kind: Shares withheld solely for the purpose of satisfying tax liability due upon vesting of restricted stock award. Read SEC document |
| May 05, 2020 Filed May 7, 2020 23:06 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 102 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-20-003473 · primarydocument.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, CAO & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591.8868 F1 · price: This award vests in 3 equal annual installments beginning on 5/5/2021. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.